Abstract. B-type erythropoietin-producing hepatocellular (EphB) receptors and their ephrin ligands are associated with aggressive behavior and poor prognosis in a number of malignancies. The aim of this study was to determine the association between the aberrant expression of these genes and prognosis in human pancreatic cancer. The expression of EphB and the ephrin ligands was determined using real-time quantitative reverse transcription PCR in 46 human primary pancreatic cancers. Overexpression of EphB2 and a more modest overexpression of ephrin-B2 mRNA were observed in more than 44% (20/46) of the pancreatic cancer specimens examined. Overexpression (>upper quartile) of EphB2 and ephrin-B2 was markedly associated with abdominal and/or back pain. Multivariate analysis identified the overexpression of EphB2 as an independent prognostic factor for disease-free and overall survival (both P<0.05). The results of the present study suggest that an increased level of ephrin-B2, in the presence of a high expression of EphB2, leads to a more aggressive tumor phenotype and that EphB2 may be used as a prognostic factor in human pancreatic cancer.
Introduction
The B-type erythropoietin-producing hepatocellular (EphB) receptor tyrosine kinases and their ephrin ligands (ephrin-Bs) are involved in crucial aspects of the embryologic development and differentiation of the nervous system (1) . However, the activities of EphB receptors and ephrin-Bs are not restricted to the neural system. Evidence suggests that certain members of the EphB family and their ligands are important in angiogenesis and oncogenesis (2) (3) (4) (5) . EphB2 and EphB3/ephrin-B signalling regulates cell sorting and cell migration through contact-mediated cell repulsion (6, 7) . Overexpression of EphB2, EphB4 and ephrin-B1 has been described in gastric, colon and breast cancers (8) (9) (10) (11) (12) . Although the ephrin-Eph system plays a number of roles in malignant tumors, to the best of our knowledge, little is known regarding its expression and role in pancreatic cancer. In the present study, we investigated the expression patterns of ephrin-B and EphB mRNA in a series of human pancreatic cancers and assessed the clinical significance of the gene expression to clinicopathological characteristics and patient prognosis.
Patients and methods
Patients. Cancer specimens from 46 patients with pancreatic cancer were obtained following partial duodenopancreatectomy (Whipple resection) at The First Affiliated Hospital of Xi'an Jiaotong University (Shaanxi, China), after obtaining informed consent from patients and approval by the ethics committee of the university. Specimens were divided into two sections. One was fixed in neutral-buffered formaldehyde and processed for histopathological evaluation and the other section was immediately frozen in liquid nitrogen and stored at -80˚C until use for the EphB and ephrin-B mRNA extraction and subsequent real-time quantitative reverse transcription PCR (qRT-PCR). Two normal pancreases, one pancreatic pseudocyst and one serous cystadenoma were used as non-malignant controls.
Between Feburary 2000 and September 2004, 46 patients at The First Affiliated Hospital were consecutively diagnosed with pancreatic cancer and underwent potentially curative resection of the pathologically confirmed adenocarcinoma of the pancreas with negative resection margins (R0). The patients received gemcitabine at 1,000 mg/m 2 intravenously (IV) over 100 min every 2 weeks for 6 cycles. All 46 patients had a Karnofsky performance status of ≥60 and adequate hematologic, renal and hepatic function as defined by a standard protocol in our department. Follow-up occurred at 3-month intervals for 1 year, then 6-month intervals for 3 years and yearly thereafter. Table I . For EphB and ephrin-B amplification, 95˚C (90 sec) for the hot start was followed by 42 rounds of amplification at 95˚C (0 sec) for denaturation, 50˚C (10 sec) for annealing and 72˚C (10 sec) for extension, with a temperature slope of 20˚C/sec, performed in the LightCycler. The same temperature profile was used for all experiments, except for an annealing temperature of 55˚C for β-actin. External standards for EphB and ephrin-B mRNA and β-actin were known concentrations of MCF7 cell line (human breast cancer cell line) RNA prepared by 10-fold serial dilutions. Each run consisted of five external standards, a negative control without a template and the patient samples. Relative mRNA in each sample was then automatically quantitated by reference to the standard curve constructed each time according to the LightCycler software.
Statistical analysis. Statistical analysis was performed using the SPSS-PC package (version 13.0; SPSS, Chicago, IL, USA). The χ 2 and Fisher's exact tests were used to analyze the association between the expression of the EphB and ephrin-B genes, measured by qRT-PCR, and the clinicopathological features of pancreatic cancer. The thresholds (upper quartiles) were defined as positive or overexpression of the genes. Diseasefree and overall survival endpoints were analyzed. Survival time was calculated from the date of diagnosis until mortality (for overall survival) or, if the patient was still alive, until the last follow-up visit (disease-free and overall survival). Local, regional or distant tumor progression was taken into account as adverse events for disease-free survival. Mortality from any cause was considered for overall survival. The Kaplan-Meier method with the log-rank test was used to calculate survival rates and differences in survival curves. The Cox proportional hazards regression model with a stepwise procedure was used to analyze the simultaneous effect of prognostic factors. P<0.05 was considered to indicate a statistically significant result.
Results
Gene expression. Initially, the expression of 7 EphB and ephrin-B genes (EphB1-4,6 and ephrin-B1,2) were screened by real-time qRT-PCR on two normal pancreases, one pancreatic pseudocyst, one serous cystadenoma, as well as five pancreatic cancer specimens. The expression levels of EphB1, B3, B4, B6 and ephrin-B1 were relatively low in the normal and tumour samples and these genes were not considered further. Thus, EphB2 and ephrin-B2 were selected for further analysis. No significant differences were found between the overexpressed and non-overexpressed EphB2 and ephrin-B2 groups with regard to age, gender or histological differentiation.
Distribution of the EphB and ephrin-B genes in a series

Correlation between EphB2 and ephrin-B2 expression status and clinicopathological characteristics.
Overexpression of EphB2 and ephrin-B2 in pancreatic cancer specimens was more common in the the presence of lymph node metastasis (75.0 vs. 34.6% and 70.0 vs. 38.4%, respectively; P<0.05), in the classification of T factor (T1 plus T2 vs. T3 plus T4: 75.0 vs. 23.1% and 65.0 vs. 30.7%, respectively; P<0.05) and in the degree of pain (90.0 vs. 30.7% and 85.0 vs. 34.6%, respectively; P<0.05; Table II) .
Uni-and multivariate analyses of prognostic factors in pancreatic cancer patients. One-year disease-free and overall survival rates were 39.0 and 30.0%, respectively ( Figs. 1 and 2) . Forty-one patients had a tumor when they died and 38 patients experienced recurrence of a tumor: 21 in the liver, 10 in the lymph node, 3 in the peritoneum and 4 in other organs.
The prognostic significance of the expression of EphB2 and ephrin-B2 was analyzed for the disease-free and overall survival rates. Patients with a low EphB2 and ephrin-B2 expression had better 1-year survival rates than those with a high expression (disease-free, 55 vs. 15% and 43 vs. 35%; overall, 52 vs. 0% and 44 vs. 11%; all P<0.05; Table III ). Univariate analysis revealed that the EphB2 and ephrin-B2 expression level, presence of lymph node metastasis, histological differentiation, the degree of pain and T stage of pathological tumor-node-metastasis (pTNM) staging system were significant prognosticators for disease-free and overall survival (Table III; Figs. 3 and 4). Multivariate analysis with factors proven to be significant in the univariate analysis revealed that the EphB2 expression level and T stage of the pTNM staging system were independent prognostic factors for disease-free and overall survival. The presence of lymph node metastasis is an independent prognostic factor for overall survival only (Table IV) .
Discussion
Eph receptors are the largest known family of receptor protein tyrosine kinases and are activated by interactions with cellsurface ligands termed ephrins, which are anchored on plasma membranes through either a glycosyl phosphatidylinositol linkage (ephrin-A) or a transmembrane domain (ephrin-B). The Ephs (receptors) and their ligands (ephrins) may be divided into two subclasses, A and B, on the basis of sequence homology, structure and binding affinity (1-4) . The Eph family of receptor kinases and their ligands are well known to be involved in fundamental developmental processes of the nervous system, including axon guidance, axon fasciculation, neural crest cell migration, acquisition of brain subregional identity and neuronal cell survival. Moreover, in recent years, ephrins and Ephs have been found to be expressed during the development of numerous human tumors, including melanoma, glioblastoma, lung carcinoma and breast carcinoma (2) (3) (4) (5) . However, information concerning the expression of ephrins and Ephs in pancreatic cancer is sparse. In particular, to the best of our knowledge, little is known regarding the expression and role of the different EphBs and ephrin-Bs in pancreatic cancer. In the current study, we investigated the expression Table II . Correlation between EphB2 and ephrin-B2 expression and clinicopathological characteristics of 46 patients with pancreatic cancer.
EphB2
Ephrin patterns of ephrin-B and EphB mRNA in a series of human pancreatic cancers and demonstrated that the overexpression of EphB2 is correlated with progression and pain in human pancreatic cancer. Our observations indicate that EphB1, B3, B4, B6 and ephrin-B1 are coordinately silenced in the majority of pancreatic cancers and non-tumorous samples. The mechanism of the silencing of EphB expression in pancreatic cancer and non-tumorous samples remains uncharacterized, but in the great majority of cancers, downregulation of EphB receptors occurs at the mRNA level (4,7)
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. Our results clearly demonstrate that the overexpression of EphB2 and ephrin-B2 had a significantly higher incidence with lymph node metastasis, advanced classification of T factor and a higher degree of pain. Patients with low EphB2 and ephrin-B2 expression yielded better 1-year survival rates than those with a high expression. The proportion of individuals surviving pancreatic cancer is extremely low and the length of time between diagnosis and mortality is typically short, usually less than six months (13) . Approximately 2 out of 10 individuals with pancreatic cancer live for at least one year after their cancer is found. Fewer than 4% are likely to be alive after 5 years (http://www.cancerstaging.org/) (13) . Thus, 1-year rates were used as the standard way of looking at a patient's outlook in this study. Multivariate analysis identified the level of EphB2 expression as an independent prognostic factor for disease-free and overall survival (P<0.01, P<0.0001, respectively). Our results are consistent with those of previous studies, which indicated that an increased expression of EphB2 in breast cancer was associated with poor overall survival and that there was a clear trend that high levels of the EphB2 protein were negatively associated with disease-free survival. However, this is contrary to previous data presented in colorectal cancer that suggest that EphB2 expression is a good prognostic factor. The discrepancy may be explained by fundamental differences in the role of EphB2 in cancers of the solid and hollow organs. The Eph receptor families and their ligands are well known to signal complicated cell processes, which may result in distinct or occasionally even opposing effects on cell behaviour depending on context (14) . Pain affects cancer prognosis and has been shown to be an independent prognostic factor in pancreatic cancers (13) . Overexpression of EphB2 is correlated with a higher degree of pain, the mechanism for which is not yet apparent. However, the ephrin-B-EphB receptor signalling has been shown to contribute to neuropathic pain by regulating excitability of nociceptive-related neurons in dorsal root ganglion and dorsa horn and the synaptic plasticity at the spinal level (15) . Moreover, ephrin-B2 siRNA may be a potential therapeutic agent for neuropathic pain (16) .
In conlusion, high levels of EphB2 expression are associated with shortened survival in patients with pancreatic cancer and multivariate analyses suggest that EphB2 is an independent prognostic factor. The Eph family of receptor tyrosine kinases is an attractive candidate for therapeutic targets. Previous studies have developed a monoclonal antibody, peptide or small molecules against EphB2 in an attempt to block its activation (17) (18) (19) , which may be applied as a potential remedy in pancreatic cancer as there are few treatment options available for patients with a disease with such a high mortality rate, resulting in poor outcomes.
